InvestSMART

The article you are trying to access does not exist, however, here are some articles you may be interested in.

Orthocell Limited (ASX:OCC)

ALERT: Price-sensitive ASX Announcement for OCC
Current share price for OCC : $0.720 -0.13 (-15.29%)+
Announcement
Release
14 Jul 2026 8:47AM
Price at Release
$0.850
Full Release
download
Summary
Orthocell Limited's Q4 FY26 ASX Investor Presentation highlights a strong quarter with significant growth driven by the commercialization of Remplir in the U.S. The presentation outlines key achievements, including expanding the distributor network to over 20 states covering about 50% of the U.S. population and onboarding 76 surgeons. Remplir sales resulted in a $3.8M revenue for Q4, representing a 20% growth from the previous quarter, and contributed significantly to the 44% year-on-year revenue growth for FY26. The company maintains a solid liquidity position with $44.1 million in available funds, anticipating no need for additional funding. Looking ahead, the company targets further expansion in the U.S. market, aiming for 80% distributor coverage and increased surgeon engagement. Orthocell is also progressing regulatory activities in the EU/UK and advancing its product pipeline.
Key Points
  • Orthocell reported $3.8M revenue in Q4 FY26, marking a 20% quarterly growth.
  • Achieved 44% year-on-year revenue growth for FY26.
  • Expanded U.S. distributor network to cover 50% of the population across 20+ states.
  • 76 surgeons purchased Remplir, exceeding expectations.
  • Orthocell maintains a cash reserve of $44.1 million.
  • Targeting 80% U.S. distributor coverage and 150-200 surgeons onboarded.
  • Progress in EU/UK regulatory submissions and product pipeline development.
  • Significant global market opportunity for Remplir in nerve repair.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.